- Home
- TTI vs ATXS Comparison
TTI vs ATXS Comparison
Compare TTI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTI
- ATXS
- Stock Information
- Founded
- TTI 1981
- ATXS 2008
- Country
- TTI United States
- ATXS United States
- Employees
- TTI N/A
- ATXS N/A
- Industry
- TTI Oil & Gas Production
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- TTI Energy
- ATXS Health Care
- Exchange
- TTI Nasdaq
- ATXS Nasdaq
- Market Cap
- TTI 761.0M
- ATXS 676.1M
- IPO Year
- TTI 1990
- ATXS 2015
- Fundamental
- Price
- TTI $7.17
- ATXS $12.39
- Analyst Decision
- TTI Strong Buy
- ATXS Buy
- Analyst Count
- TTI 3
- ATXS 7
- Target Price
- TTI $7.00
- ATXS $30.00
- AVG Volume (30 Days)
- TTI 3.9M
- ATXS 4.2M
- Earning Date
- TTI 10-28-2025
- ATXS 11-12-2025
- Dividend Yield
- TTI N/A
- ATXS N/A
- EPS Growth
- TTI 7085.43
- ATXS N/A
- EPS
- TTI 0.92
- ATXS N/A
- Revenue
- TTI $618,755,000.00
- ATXS N/A
- Revenue This Year
- TTI $3.84
- ATXS N/A
- Revenue Next Year
- TTI $4.07
- ATXS N/A
- P/E Ratio
- TTI $7.85
- ATXS N/A
- Revenue Growth
- TTI 0.17
- ATXS N/A
- 52 Week Low
- TTI $2.03
- ATXS $3.56
- 52 Week High
- TTI $8.20
- ATXS $12.72
- Technical
- Relative Strength Index (RSI)
- TTI 57.09
- ATXS 76.47
- Support Level
- TTI $6.70
- ATXS $12.40
- Resistance Level
- TTI $7.99
- ATXS $12.72
- Average True Range (ATR)
- TTI 0.48
- ATXS 0.21
- MACD
- TTI -0.10
- ATXS -0.04
- Stochastic Oscillator
- TTI 31.10
- ATXS 68.29
About TTI Tetra Technologies Inc.
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.